Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05465226 · ClinicalTrials.gov registry record · Phase 4
Oliceridine in Patients With Acute Burn Injuries
A Phase 4 study, sponsored by University of Tennessee.
- Completed
- Registry status
- Phase 4
- Development phase
- 31
- Enrollment target
NCT05465226 is a Phase 4 study that has completed, run by University of Tennessee. The registered enrollment target is 31 participants.
The verdict
NCT05465226, a Phase 4 study, has completed, sponsored by University of Tennessee.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 31 participants
- Enrollment target
Study Summary
Pain after acute burn injury is complex with much still not understood. The primary mechanism is believed to be nociceptive, but is interwoven with aspects of somatogenic, neuropathic, and psychogenic pathways. As such, opioid receptor agonists are an essential component for pain management after burn injury. The majority of wound care and dressing changes are completed in non-intubated patients and rates of respiratory depression concerning. Oliceridine is a biased, selective MOR agonist approved for treatment of acute pain. To date there is no literature of use in patients with burn injuries. While it should be effective, efficacy and the potential for reduced adverse events need to be quantified. Current practice and guidelines, plead for better analgesia for patients with burn injuries.
Interventions
- DRUG Oliceridine
- DRUG Historical opioid use
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2023-04-01 |
| Est. Completion | 2023-10-24 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05465226
The ClinicalTrials.gov registry entry for NCT05465226 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Tennessee, which has 96 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Oliceridine is the first listed.
NCT05465226 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05465226 about?
NCT05465226 is a clinical study titled "Oliceridine in Patients With Acute Burn Injuries". Pain after acute burn injury is complex with much still not understood. The primary mechanism is believed to be nociceptive, but is interwoven with aspects of somatogenic, neuropathic, and psychogenic pathways. As such, opioid receptor agonists are an essential component for pain management after bu...
What is the current status of trial NCT05465226?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 31 participants. The study started on 2023-04-01. Estimated completion is 2023-10-24.
What interventions are being tested in trial NCT05465226?
The interventions under investigation include: Oliceridine (DRUG), Historical opioid use (DRUG).
Who is sponsoring clinical trial NCT05465226?
This trial is sponsored by University of Tennessee, which has 96 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.